BEZALIP

Main information

  • Trade name:
  • BEZALIP 400 mg prolonged-release tablet
  • Dosage:
  • 400 mg
  • Pharmaceutical form:
  • prolonged-release tablet
  • Prescription type:
  • Prescription only
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • BEZALIP 400 mg prolonged-release tablet
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Bezafibrate
  • Product summary:
  • Suitability for use in older adult patients Bezafibratum Suitable for older persons, with specific cautions. Reduce the dose in even mild renal insufficiency. Do not use in moderate and severe renal insufficiency. Take interactions into account, especially with statins and warfarin.

Other information

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 13941
  • Authorization date:
  • 24-08-2010
  • Last update:
  • 26-07-2018